Omid Hamid, M.D.

Omid Hamid, M.D.



Dr. Omid Hamid is one of the oncology and hematology specialists who are currently affiliated with Cedars-Sinai Marina del Rey Hospital. He received his medical degree from the University of Southern California Keck School of Medicine and completed his residency at the Los Angeles County Hospital and University of Southern California Medical Center. Dr. Omid Hamid is recognized nationally and internationally as a key opinion leader in immuno-oncologic drug development and melanoma therapeutics. By virtue of his role as Chief of Immunotherapy and Translational Research, numerous patients have benefited from innovative, effective, paradigm-shifting drugs.

The physician was a key investigator in the initial clinical trials with Ipilimumab, Pembrolizumab, Nivolumab, Atazolizumab, and Vemurafenib, agents that led to considerable survival benefits in the lives of patients. The medical expert has offered his opinion in numerous articles in the online publication OncLive. Dr. Omid Hamid has presented his research at major national and international meetings, including the American Society of Clinical Oncology and the Society for Melanoma Research. He has published manuscripts, abstracts, and reviews on immunotherapy, targeted therapy, and melanoma care in prestigious journals such as the Journal of Clinical Oncology, the New England Journal of Medicine, and Clinical Cancer Research.

Insurance Accepted

  • Aetna Choice POS II
  • Cigna
  • Great West PPO
  • First Health PPO
  • Multiplan PPO

Languages Spoken

  • English
  • Farsi
  • Spanish

Education & Training

Medical Degree

University of Southern California Keck School of Medicine

Internship(s)

University of Southern California Medical Center

Residency(ies)

University of Southern California - LAC+USC Medical Center

Fellowship(s)

University of Southern California - LAC+USC Medical Center



Publications & Media